Yellow Fever Vaccine
7
1
2
3
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
0.0%
0 terminated out of 7 trials
100.0%
+13.5% vs benchmark
14%
1 trials in Phase 3/4
0%
0 of 3 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 3 completed trials
Clinical Trials (7)
VAC-SIP-YF (Vaccination- Safety & Immunogenicity During Pregnancy- Yellow Fever)
"Persistence of Neutralizing Antibodies Against Yellow Fever (YF) in HIV-infected Patients"
Characterization of Human Memory Immune Responses to Prior Yellow Fever Vaccination
Immunity Period After One Dose of Yellow Fever Vaccine in Adults and Children (Paraiba Study)
Duration of Immunity 10 Years After a Dose-response Study With Yellow Fever Vaccine - Complementary Study
Yellow Fever Vaccine on Statin/ Non Statin Subjects
Clinical Study of Immunity Duration of Yellow Fever Vaccine in Military